Senior management

We have a talented, experienced, knowledgeable senior management team at Vernalis. They lead our commercial pipeline, manage our research programmes and oversee our partner collaborations. They also ensure that the company is well run at all levels. Key members of the management team include:

Ian Garland, Chief Executive Officer

Ian Garland became Chief Executive Officer in December 2008. From May 2007 until September 2008, Ian was CEO of Acambis plc.  During this period he oversaw a series of important advances culminating in the company's acquisition by Sanofi-Aventis in September 2008 for £280m. From 2004 to 2007, Ian served as CFO of Arrow Therapeutics Ltd., a privately-held company engaged in the discovery and development of new anti-viral agents until its acquisition by AstraZeneca plc for US$150m in February 2007. Before this Ian was President and Chief Operating Officer of Celltech Pharmaceuticals Inc., which had a turnover of around US$300 million encompassing the US operations of Celltech Group plc. From 1988 to 1995 Ian worked at KPMG, specialising in the pharmaceutical sector, following qualification as a Chartered Accountant.

David Mackney, Chief Financial Officer

David Mackney was appointed as Chief Financial Officer on 2 February 2009. Prior to joining Vernalis David worked with Ian as Interim CFO at Acambis plc, working to successfully secure the US biodefence contract, the secondary financing and the acquisition of Acambis by Sanofi-Aventis. Prior to Acambis, David was CFO for a private equity-backed technology company and served as Group Financial Controller at Shire plc.  From 1996 to 2001, David worked as a senior manager in audit and then in transaction services at Arthur Andersen. He is a Chartered Accountant.

Mike Wood, Research Director

Mike Wood became Research Director in February 2004.  Since then, he has overseen the continued strengthening of capabilities in structure and fragment based drug discovery.  Mike's focus has been on the pragmatic adaptation of the most effective methods for rapid assessment of therapeutic targets and driving projects to deliver clinical candidates. The current therapeutic focus for Vernalis research is oncology and in particular drug targets relating to cancer metabolism.  Before becoming our Research Director, Mike was the Head of Pre-clinical Development for Ribotargets and prior to that Director of Biology at British Biotech.  Mike started his industrial career at Smith Kline and French in 1986.

Susan Wallcraft, Group General Counsel and Company Secretary

Susan Wallcraft joined Vernalis in January 2018 as Group General Counsel and Company Secretary. Prior to joining Vernalis, Susan was General Counsel and Company Secretary for the Wellcome Trust and before that she spent 10 years at Pfizer in increasingly senior legal roles, the last being Assistant General Counsel for the Primary Care business in Europe, Canada, Australia and New Zealand. Susan qualified as a solicitor in 1992 and began her career at CMS in the City specialising in corporate transactions in the Pharmaceutical sector.

Donna Radzik, SVP Pharmaceutical Quality Operations

Donna Radzik joined Vernalis in February 2014. She oversees all facets of technical operations, including quality, contract manufacturing, regulatory, supply chain and distribution. Donna has extensive experience managing drug substance and product technical development, commercial manufacture/supply chain and global quality systems. Prior to joining, Donna headed a consultancy providing pharmaceutical technical and quality support. Donna has also held senior leadership roles at Aveo Oncology, Sanofi Pasteur Biologics (formerly Acambis), UCB Pharma and Celltech/Medeva. Donna has a PhD in Analytical Chemistry from Purdue University.




Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and or FDA at 1-800-FDA-1088 or